Aug. 24 at 9:13 AM
High Potential biotech stocks of the week:
$ATYR : Phase 3 results expected in mid September for Efzofitimod (pulmonary fibrosis), float ~96 M mostly institution-owned, rising volumes → bullish consolidation above MAs, breakout likely if FDA anticipation builds.
$OTLK : PDUFA on August 27 for LYTENAVA™, already approved in EU/UK with first sales, reduced float ~25 M and short ~9% → strong asymmetry if FDA gives green light, technical setup bullish above moving averages.
$LSTA : Cash runway through end of 2026, multiple near-term clinical milestones (ASCEND, BOLSTER, iLSTA), targeting hard-to-treat solid tumors like pancreatic cancer → strong asymmetry with x3–x5 upside potential in coming months.
$MBOT : FDA approval expected Q3 for LIBERTY® system, cash ~32 M covering 12 months, float ~17 M with ~8% short interest → bullish pattern + potential squeeze, tight Bollinger bands signaling expansion.
